Welcome to Paid Research Studies


Browse Locations ... United States» ... Massachusetts» ... Cambridge






  • Condition:   Behcet's Disease Uveitis
    Interventions:   Drug: Placebo;   Drug: Gevokizumab
    Sponsor:   XOMA (US) LLC
    Recruiting - verified November 2014

  • Condition:   Sepsis
    Interventions:   Other: IV fluids;   Other: Hospital Notification
    Sponsors:   Massachusetts General Hospital;   Pro EMS;   Mount Auburn Hospital
    Recruiting - verified November 2014

  • Condition:   Spinal Cord Injury
    Interventions:   Other: FES-row-training;   Other: Arms-only-row training
    Sponsors:   Spaulding Rehabilitation Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2014

  • Condition:   Mental Disorders
    Interventions:   Behavioral: DECIDE-PA;   Behavioral: DECIDE-PC
    Sponsors:   Cambridge Health Alliance;   Patient Centered Outcome Research Institute
    Recruiting - verified November 2014

  • Condition:   Uveitis
    Interventions:   Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
    Sponsors:   XOMA (US) LLC;   Institut de Recherches Internationales Servier
    Recruiting - verified November 2014

  • Condition:   Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
    Intervention:  
    Sponsors:   Genentech, Inc.;   Accord Healthcare, Inc.;   Sandoz Inc.;   Apotex Corporation;   Novartis Pharmaceuticals;   Pfizer;   Mylan Pharmaceuticals;   Teva Pharmaceuticals USA;   Alkem Laboratories Ltd;   Roxane Laboratories;   Vintage Pharmaceuticals, LLC
    Recruiting - verified November 2014

  • Condition:   Uveitis
    Interventions:   Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
    Sponsors:   XOMA (US) LLC;   Institut de Recherches Internationales Servier
    Recruiting - verified November 2014

  • Condition:   Hormone Receptor Positive Malignant Neoplasm of Breast
    Intervention:   Device: MammaPrint
    Sponsor:   Agendia
    Recruiting - verified November 2014

  • Condition:   Uvea; Posterior, Disorder
    Interventions:   Drug: DE-109;   Drug: DE-109;   Drug: DE-109
    Sponsor:   Santen Inc.
    Recruiting - verified June 2011

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Infant, Newborn;   Infant, Low Birth Weight;   Infant, Small for Gestational Age;   Infant, Premature
    Intervention:  
    Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Center for Research Resources (NCRR)
    Recruiting - verified September 2014

  • Conditions:   Infant, Newborn;   Infant, Low Birth Weight;   Infant, Small for Gestational Age;   Infant, Premature
    Intervention:  
    Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Center for Research Resources (NCRR)
    Recruiting - verified September 2014